Literature DB >> 27920122

MicroRNA-33 Controls Adaptive Fibrotic Response in the Remodeling Heart by Preserving Lipid Raft Cholesterol.

Masataka Nishiga1, Takahiro Horie1, Yasuhide Kuwabara1, Kazuya Nagao1, Osamu Baba1, Tetsushi Nakao1, Tomohiro Nishino1, Daihiko Hakuno1, Yasuhiro Nakashima1, Hitoo Nishi1, Fumiko Nakazeki1, Yuya Ide1, Satoshi Koyama1, Masahiro Kimura1, Ritsuko Hanada1, Tomoyuki Nakamura1, Tsukasa Inada1, Koji Hasegawa1, Simon J Conway1, Toru Kita1, Takeshi Kimura1, Koh Ono2.   

Abstract

RATIONALE: Heart failure and atherosclerosis share the underlying mechanisms of chronic inflammation followed by fibrosis. A highly conserved microRNA (miR), miR-33, is considered as a potential therapeutic target for atherosclerosis because it regulates lipid metabolism and inflammation. However, the role of miR-33 in heart failure remains to be elucidated.
OBJECTIVE: To clarify the role of miR-33 involved in heart failure. METHODS AND
RESULTS: We first investigated the expression levels of miR-33a/b in human cardiac tissue samples with dilated cardiomyopathy. Increased expression of miR-33a was associated with improving hemodynamic parameters. To clarify the role of miR-33 in remodeling hearts, we investigated the responses to pressure overload by transverse aortic constriction in miR-33-deficient (knockout [KO]) mice. When mice were subjected to transverse aortic constriction, miR-33 expression levels were significantly upregulated in wild-type left ventricles. There was no difference in hypertrophic responses between wild-type and miR-33KO hearts, whereas cardiac fibrosis was ameliorated in miR-33KO hearts compared with wild-type hearts. Despite the ameliorated cardiac fibrosis, miR-33KO mice showed impaired systolic function after transverse aortic constriction. We also found that cardiac fibroblasts were mainly responsible for miR-33 expression in the heart. Deficiency of miR-33 impaired cardiac fibroblast proliferation, which was considered to be caused by altered lipid raft cholesterol content. Moreover, cardiac fibroblast-specific miR-33-deficient mice also showed decreased cardiac fibrosis induced by transverse aortic constriction as systemic miR-33KO mice.
CONCLUSION: Our results demonstrate that miR-33 is involved in cardiac remodeling, and it preserves lipid raft cholesterol content in fibroblasts and maintains adaptive fibrotic responses in the remodeling heart.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  atherosclerosis; fibroblasts; fibrosis; heart failure; microRNAs

Mesh:

Substances:

Year:  2016        PMID: 27920122     DOI: 10.1161/CIRCRESAHA.116.309528

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  23 in total

1.  Genetic deficiency or pharmacological inhibition of miR-33 protects from kidney fibrosis.

Authors:  Nathan L Price; Verónica Miguel; Wen Ding; Abhishek K Singh; Shipra Malik; Noemi Rotllan; Anna Moshnikova; Jakub Toczek; Caroline Zeiss; Mehran M Sadeghi; Noemi Arias; Ángel Baldán; Oleg A Andreev; Diego Rodríguez-Puyol; Raman Bahal; Yana K Reshetnyak; Yajaira Suárez; Carlos Fernández-Hernando; Santiago Lamas
Journal:  JCI Insight       Date:  2019-11-14

2.  Perivascular cell αv integrins as a target to treat skeletal muscle fibrosis.

Authors:  Pedro H D M Prazeres; Anaelise O M Turquetti; Patrick O Azevedo; Rodrigo S N Barreto; Maria A Miglino; Akiva Mintz; Osvaldo Delbono; Alexander Birbrair
Journal:  Int J Biochem Cell Biol       Date:  2018-04-05       Impact factor: 5.085

Review 3.  Protective transcriptional mechanisms in cardiomyocytes and cardiac fibroblasts.

Authors:  Cameron S Brand; Janet K Lighthouse; Michael A Trembley
Journal:  J Mol Cell Cardiol       Date:  2019-04-28       Impact factor: 5.000

Review 4.  MicroRNAs and lipid metabolism.

Authors:  Binod Aryal; Abhishek K Singh; Noemi Rotllan; Nathan Price; Carlos Fernández-Hernando
Journal:  Curr Opin Lipidol       Date:  2017-06       Impact factor: 4.776

5.  Loss of hepatic miR-33 improves metabolic homeostasis and liver function without altering body weight or atherosclerosis.

Authors:  Nathan L Price; Xinbo Zhang; Pablo Fernández-Tussy; Abhishek K Singh; Sean A Burnap; Noemi Rotllan; Leigh Goedeke; Jonathan Sun; Alberto Canfrán-Duque; Binod Aryal; Manuel Mayr; Yajaira Suárez; Carlos Fernández-Hernando
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-02       Impact factor: 11.205

Review 6.  Lipid rafts as a therapeutic target.

Authors:  Dmitri Sviridov; Nigora Mukhamedova; Yury I Miller
Journal:  J Lipid Res       Date:  2020-03-23       Impact factor: 5.922

7.  Phenotype-genotype network construction and characterization: a case study of cardiovascular diseases and associated non-coding RNAs.

Authors:  Rongrong Wu; Yuxin Lin; Xingyun Liu; Chaoying Zhan; Hongxin He; Manhong Shi; Zhi Jiang; Bairong Shen
Journal:  Database (Oxford)       Date:  2020-01-01       Impact factor: 3.451

Review 8.  High-density lipoprotein-mediated cardioprotection in heart failure.

Authors:  Ampadu O Jackson; Jun Meng; Huifang Tang; Kai Yin
Journal:  Heart Fail Rev       Date:  2021-07       Impact factor: 4.214

Review 9.  MicroRNA regulation of cholesterol metabolism.

Authors:  Kathryn M Citrin; Carlos Fernández-Hernando; Yajaira Suárez
Journal:  Ann N Y Acad Sci       Date:  2021-01-31       Impact factor: 5.691

Review 10.  MicroRNAs and Circular RNAs in Lipoprotein Metabolism.

Authors:  Pablo Fernández-Tussy; Inmaculada Ruz-Maldonado; Carlos Fernández-Hernando
Journal:  Curr Atheroscler Rep       Date:  2021-05-10       Impact factor: 5.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.